BLACK BOX WARNING
- increased mortality in elderly patients with dementia-related psychosis
chlorpromazine
Brand: Thorazine
⚠ BBW Beers Criteria Prototype Drug
Drug Class: first-generation antipsychotic (FGA)
Drug Family: antipsychotic
Subclass: low-potency phenothiazine
Organ Systems: cns
Mechanism of Action
Blocks D2 dopamine receptors in the mesolimbic pathway (antipsychotic effect) and tuberoinfundibular pathway (hyperprolactinemia). Wide receptor promiscuity including alpha-1, H1, and muscarinic blockade accounts for its extensive side effect profile. The first antipsychotic drug, developed in 1952.
D2 dopamine receptoralpha-1 adrenergic receptorH1 histamine receptormuscarinic receptors5-HT2A receptor
Indications
- schizophrenia
- acute agitation
- intractable hiccups
- nausea and vomiting
- off-label: mania
Contraindications
- concurrent CNS depressants (relative)
- bone marrow depression
- QT prolongation
Adverse Effects
Common
- sedation (prominent)
- orthostatic hypotension
- anticholinergic effects
- photosensitivity
- weight gain
- hyperprolactinemia
Serious
- extrapyramidal symptoms (EPS)
- tardive dyskinesia
- neuroleptic malignant syndrome (NMS)
- QT prolongation
- agranulocytosis (rare)
Pharmacokinetics (ADME)
| Absorption | variable oral bioavailability (~32%); IM absorption more reliable |
| Distribution | highly lipophilic; protein binding ~95-98%; large Vd; accumulates in tissues |
| Metabolism | extensively hepatic via CYP2D6 and CYP1A2; >10 metabolites |
| Excretion | renal and biliary |
| Half-life | 8-35 hours |
| Onset | 30-60 minutes (IM); 30-60 minutes (oral) |
| Peak | 2-4 hours (oral) |
| Duration | 4-6 hours per dose |
| Protein Binding | 95-98% |
| Vd | ~20 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| CNS depressants | additive sedation | major |
| antihypertensives | additive hypotension via alpha-1 blockade | moderate |
| anticholinergics | additive anticholinergic effects | moderate |
| lithium | increased neurotoxicity risk | moderate |
Nursing Considerations
- Monitor blood pressure for orthostatic hypotension; low-potency phenothiazines have the highest alpha-1 blockade among antipsychotics — have patient sit before standing.
- Assess for extrapyramidal symptoms: akathisia (subjective restlessness), parkinsonian tremor/rigidity, acute dystonia (neck stiffness, tongue protrusion) — report immediately as dystonia responds to diphenhydramine or benztropine.
- Protect patient from sunlight; photosensitivity can cause severe burns — apply SPF 30+ sunscreen when outdoors.
- Neuroleptic malignant syndrome (NMS) may occur at any time: fever, muscle rigidity, altered consciousness, and autonomic instability — discontinue immediately and treat as emergency.
Clinical Pearls
- Chlorpromazine's discovery in 1952 revolutionized psychiatry, enabling deinstitutionalization of millions of patients with schizophrenia; it is the 'prototype' of all antipsychotic drugs.
- Low-potency antipsychotics like chlorpromazine cause more sedation, hypotension, and anticholinergic effects but fewer EPS compared to high-potency drugs like haloperidol — a clinically useful distinction.
Safety Profile
Pregnancy use-with-caution
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.